Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Biogen BIIB and Japan-based partner ... We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 ...

Biogen currently owns a 10.2% stake in SAGE ... You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

Biogen currently owns a 10.2% stake in SAGE ... 498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ...

Biogen has an Earnings ESP of +0.49% at the ... but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing ...

The Board also revealed that it has unanimously rejected an unsolicited, nonbinding proposal from Biogen Inc. (BIIB ... up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at ...

Biogen and Eisai remain confident that these ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment. Eisai Co., Ltd. and Biogen Inc. announced that the U.S. FDA ...

Our analysis of options history for Biogen (NASDAQ:BIIB) revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all ...